



## Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023

October 3, 2023 at 7:00 AM EDT

PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- [Amicus Therapeutics](#) (Nasdaq: FOLD), today announced that one oral presentation and four posters highlighting its development program for Pompe disease will be included at the [28th Annual Congress of the World Muscle Society \(WMS\)](#), being held October 3-7, 2023 in Charleston, SC.

### **Oral Presentation:**

**Abstract Title:** *104-week efficacy and safety of cipaglucosidase alfa + miglustat in patients with late-onset Pompe disease previously treated with alglucosidase alfa (Oral #O21)*

- **Presenter:** Tahseen Mozaffar, MD, Department of Neurology, University of California, Irvine, CA, U.S.A.
- **Date and time:** Saturday, October 7, 7:45-8:45 a.m. E.T.
- **Location:** PAC, Charleston Area Convention Center

### **Poster Sessions:**

**Abstract Title:** *Switching treatment to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease (Poster #P371)*

- **Presenter:** Kristl G. Claeys, MD, PhD, University Hospitals Leuven, Leuven, Belgium
- **Poster Session 3:** Friday, October 6, 2:00-3:00 p.m. E.T.
- **Location:** Ballroom A-C, Charleston Area Convention Center

**Abstract Title:** *Effect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL (Poster #P373)*

- **Presenter:** Jordi Díaz-Manera, MD, PhD, John Walton Muscular Dystrophy Research Centre, Newcastle upon Tyne, U.K.
- **Poster Session 3:** Friday, October 6, 2:00-3:00 p.m. E.T.
- **Location:** Ballroom A-C, Charleston Area Convention Center

**Abstract Title:** *Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials (Poster #P372)*

- **Presenter:** Barry J. Byrne, MD, PhD, University of Florida, Gainesville, FL, U.S.A.
- **Poster Session 3:** Friday, October 6, 2:00-3:00 p.m. E.T.
- **Location:** Ballroom A-C, Charleston Area Convention Center

**Abstract Title:** *Disease burden, treatment patterns and healthcare resource utilization associated with Pompe disease in Sweden: a real-world evidence study (ePoster #VP369)*

- **Presenter:** Christopher Lindberg, MD, Neuromuscular Centre, Sahlgrenska University Hospital, Gothenburg, Sweden
- **Poster Session 3:** Friday, October 6, 2:00-3:00 p.m. E.T.
- **Location:** Virtual Platform

For more information on the World Muscle Society 2023, please visit [wms2023.com](#).

### **About Amicus Therapeutics**

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company's website at [www.amicusrx.com](#), and follow on [Twitter](#) and [LinkedIn](#).

### **CONTACTS:**

#### **Investors:**

Amicus Therapeutics  
Andrew Faughnan  
Vice President, Investor Relations  
[afaughnan@amicusrx.com](mailto:afaughnan@amicusrx.com)  
(609) 662-3809

**Media:**

Amicus Therapeutics

Diana Moore

Head of Global Corporate Communications

[dmoore@amicusrx.com](mailto:dmoore@amicusrx.com)

(609) 662-5079

FOLD-G